BPI on the Medical Research Act: Pain points lie in pricing

“For the pharmaceutical industry, confidential reimbursement amounts, such as those provided for in the draft medical research law passed by the Federal Cabinet today, can only become relevant in individual cases,” says Prof Dr. Jens Peters, Head of Clinical Research at the Federal Association of the Pharmaceutical Industry (BPI). “Because this new regulation causes additional…

Those